FULBRIGHT & JAWORSKI L.L.P.

A REGISTERED LIMITED LIABILITY PARTNERSHIP 600 CONGRESS AVENUE, SUITE 2400 AUSTIN, TEXAS 78701 AAU 1643

HOUSTON
WASHINGTON. D.C.
AUSTIN
SAN ANTONIO
DALLAS
NEW YORK
LOS ANGELES
MINNEAPOLIS
LONDON
HONG KONG

FILE: VBLT:002

CERTIFICATE OF MAILING 37 C.F.R 1.8

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, DC 20231, on the date below:

Highlander

TELEPHONE: 512/418-3000 FACSIMILE: 512/474-7577

STEVEN L. HIGHLANDER

INTERNET ADDRESS: SHIGHLANDER@FULBRIGHT.COM

DIRECT DIAL: 512/418-3184

March 7, 2000

Assistant Commissioner for Patents Washington, DC 20231

MARI

SN 09/129,565 "INHIBITION OF VIRAL INFECTION AND SPREAD WITH VIRAL

AND RHOA-DERIVED PEPTIDES" - Barney S. Graham and Manoj Pastey (Client

ref. 9849)

Sir:

RE:

Enclosed for filing in the above-referenced patent application is a Supplemental Information Disclosure Statement, Form PTO-1449, references (B1, C1-C3) and an International Search Report.

No fees are believed to be due connection with the filing in Supplemental Information Disclosure Statement, however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for any reason relating to the enclosed materials, the Assistant Commissioner is hereby authorized to deduct said fees from Fulbright & Jaworski Deposit Account No. 50-1212/VBLT:002/HYL.

Please date stamp and return the enclosed postcard evidencing receipt of these materials.

Respectfully submitted,

Steven L. Highlander Reg. No. 37,642

SLH/mac

Encl: As noted

TC 1500 MAIL ROOM

CERTIFICATE OF MAILING 37 C.F.R. 1.8

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, DC 20231, on the date below:

Highlander



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Barney S. Graham Manoj Pastey

Serial No.: 09/129,565

Filed: 8/5/98

For: INHIBITION OF VIRAL INFECTION AND SPREAD WITH VIRAL AND **RHOA-DERIVED PEPTIDES**

Group Art Unit: 1643

Examiner: L. Scheiner

Atty. Dkt. No.: VBLT:002/HYL ROOM RAIL ROOM ROOM RESERVED STATEMENT. SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents Washington, D.C. 20231

Sir:

In compliance with the duty of disclosure under 37 C.F.R. § 1.56, it is respectfully requested that this Supplemental Information Disclosure Statement be entered and the documents listed on attached Form PTO-1449 be considered by the Examiner and made of record. Copies of the listed documents required by 37 C.F.R. § 1.98(a)(2) are enclosed for the convenience of the Examiner.

In accordance with 37 C.F.R §§ 1.97(g),(h), this Supplemental Information Disclosure Statement is not to be construed as a representation that a search has been made, and is not to be construed to be an admission that the information cited is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b).

In accordance with 37 C.F.R § 1.97(e)(1), Applicants hereby certify that each item of information contained in this Supplemental Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the present statement, as evidenced by the date of the enclosed search report.

Applicants respectfully request that the listed documents be made of record in the present case.

Respectfully submitted,

Steven L. Highlander

Reg. No. 37,642

Attorney for Applicants

Fulbright & Jaworski L.L.P 600 Congress Ave., Suite 2400 Austin, Texas 78701 (512) 418-3000

Date:

3/07/00